Impax Labs sued again by J&J unit Alza over generic Concerta

9 May 2011

USA-based Impax Laboratories (Nasdaq: IPXL) confirmed on Friday that Alza Corp, a division of health care giant Johnson & Johnson (NYSE: JNJ) has filed a second suit for patent infringement against the firm in the US District Court for the District of Delaware with regard to Concerta (methylphenidate hydrochloride) extended-release 18, 27 and 36mg tablets.

The company previously announced late last year, confirmation of a patent suit relating to Concerta 54mg, a treatment for attention-deficit hyperactivity disorder (ADHD) by Alza (The Pharma Letter December 2, 2010).

Impax' generic Concerta products are part of the company's strategic alliance agreement with Israeli generics giant Teva Pharmaceuticals Industries. Once the Abbreviated New Drug Application - originally filed with the US Food and Drug Administration in 2002 - is approved by the agency, Teva will commercialize the products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK